Dr. Hamilton on Phase 1 Trial for HER2 Positive Breast Cancer - Sarah Cannon

Dr Hamilton on Implications of DESTINY-Breast06 on the HER2-Low Breast Cancer ParadigmПодробнее

CAMBRIA 1: camizestrant ER+/HER2- early breast cancerПодробнее

The 2022 OncoAlert Colloquium DAY 1: Breast CancerПодробнее

The OncoAlert Colloquium Day 3 Breast CancerПодробнее

The OncoAlert Colloquium Day 3 Breast CancerПодробнее

Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast CancerПодробнее

ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast CancerПодробнее

The OncoAlert Colloquium Day 3 (Breast Cancer)Подробнее

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic TumorsПодробнее